Back to results
US 2021/0277085 A1Published application
Targeted immunotolerance
AssigneePandion Therapeutics, Inc.
InventorsNathan HIGGINSON-SCOTT, Joanne L. VINEY, Jyothsna VISWESWARAIAH, Erik Robert SAMPSON, Kevin Lewis OTIPOBY
Life of this patent
Estimating the term…
Abstract
Methods and compounds for conferring site-specific or local immune privilege.
Claims27
A polypeptide comprising a targeting moiety that binds to a target cell and an effector binding/modulating moiety, wherein the effector binding/modulating moiety is a IL-2 mutein polypeptide (IL-2 mutein), wherein the IL-2 mutein comprises the sequence of SEQ ID NO:
- 60, wherein at least one of X1, X2, X3, and X4 is I and the remainder are L or I.
4-7. (canceled)
(canceled)
21-41. (canceled)
43-55. (canceled)
57-58. (canceled)
60-63. (canceled)
65-70. (canceled)
Dependencies are inferred from the claim text.